Skip to main content
Clinical Trials/NCT03303170
NCT03303170
Completed
N/A

A Prospective, Multicenter, Randomized, Controlled, Evaluator-Blinded Study of the Safety and Effectiveness of Sebacia Microparticles as an Accessory to 1064 nm Nd:Yag Laser in the Treatment of Facial Inflammatory Acne Vulgaris

Sebacia, Inc.11 sites in 1 country168 target enrollmentSeptember 25, 2017
ConditionsAcne Vulgaris

Overview

Phase
N/A
Intervention
Not specified
Conditions
Acne Vulgaris
Sponsor
Sebacia, Inc.
Enrollment
168
Locations
11
Primary Endpoint
Change in number of inflammatory acne lesions
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Prospective, randomized, controlled, parallel group clinical study with blinded assessment evaluating Sebacia Microparticles (SM) with Nd:Yag laser in facial inflammatory acne vulgaris

Registry
clinicaltrials.gov
Start Date
September 25, 2017
End Date
April 10, 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sebacia, Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Mild to moderate acne vulgaris
  • At least 15 inflammatory acne lesions
  • Skin phototype I - III
  • Able to understand and comply with study requirements

Exclusion Criteria

  • Severe acne vulgaris
  • Nodulocystic acne
  • Ongoing use of medications and/or treatments for acne
  • New hormone regimen (used for less than 12 weeks)
  • Significant medical or mental health condition

Outcomes

Primary Outcomes

Change in number of inflammatory acne lesions

Time Frame: Week 12

Study Sites (11)

Loading locations...

Similar Trials